SG11202013175SA - Inhibitors of cyclin-dependent kinases - Google Patents
Inhibitors of cyclin-dependent kinasesInfo
- Publication number
- SG11202013175SA SG11202013175SA SG11202013175SA SG11202013175SA SG11202013175SA SG 11202013175S A SG11202013175S A SG 11202013175SA SG 11202013175S A SG11202013175S A SG 11202013175SA SG 11202013175S A SG11202013175S A SG 11202013175SA SG 11202013175S A SG11202013175S A SG 11202013175SA
- Authority
- SG
- Singapore
- Prior art keywords
- cyclin
- inhibitors
- dependent kinases
- kinases
- dependent
- Prior art date
Links
- 108091007914 CDKs Proteins 0.000 title 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 title 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862691879P | 2018-06-29 | 2018-06-29 | |
| PCT/US2019/039959 WO2020006497A1 (fr) | 2018-06-29 | 2019-06-28 | Inhibiteurs de kinases dépendantes des cyclines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202013175SA true SG11202013175SA (en) | 2021-01-28 |
Family
ID=68985220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202013175SA SG11202013175SA (en) | 2018-06-29 | 2019-06-28 | Inhibitors of cyclin-dependent kinases |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10894788B2 (fr) |
| EP (1) | EP3813819A4 (fr) |
| JP (1) | JP2021529740A (fr) |
| KR (1) | KR20210040368A (fr) |
| CN (1) | CN112638373A (fr) |
| AR (1) | AR115646A1 (fr) |
| AU (1) | AU2019291935A1 (fr) |
| BR (1) | BR112020026748A2 (fr) |
| CA (1) | CA3104131A1 (fr) |
| IL (1) | IL279791A (fr) |
| MX (1) | MX2020014245A (fr) |
| SG (1) | SG11202013175SA (fr) |
| TW (1) | TW202016094A (fr) |
| WO (1) | WO2020006497A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3787629A4 (fr) | 2018-05-02 | 2022-01-05 | Kinnate Biopharma Inc. | Inhibiteurs de kinases dépendantes des cyclines |
| SG11202013175SA (en) | 2018-06-29 | 2021-01-28 | Kinnate Biopharma Inc | Inhibitors of cyclin-dependent kinases |
| JP7608342B2 (ja) | 2018-10-01 | 2025-01-06 | ウィンターミュート バイオメディカル，インク． | 治療用組成物 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (fr) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2 |
| WO2020180959A1 (fr) * | 2019-03-05 | 2020-09-10 | Incyte Corporation | Composés de pyrazolyl pyrimidinylamine en tant qu'inhibiteurs de cdk2 |
| WO2020205560A1 (fr) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Composés sulfonylamides utilisés comme inhibiteurs de la cdk2 |
| WO2020223558A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Composés aminés tricycliques en tant qu'inhibiteurs de cdk2 |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| JP2022540671A (ja) * | 2019-07-17 | 2022-09-16 | キネート バイオファーマ インク． | サイクリン依存性キナーゼの阻害剤 |
| TW202115024A (zh) | 2019-08-14 | 2021-04-16 | 美商英塞特公司 | 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物 |
| AU2020364007A1 (en) | 2019-10-11 | 2022-04-28 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| JP2023508996A (ja) * | 2019-12-31 | 2023-03-06 | キネート バイオファーマ インク． | Ｃｄｋ１２／１３阻害剤を用いる癌の処置 |
| CA3185209A1 (fr) * | 2020-07-10 | 2021-01-27 | Alyssa WINKLER | Inhibiteurs de gas41 et leurs methodes d'utilisation |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US12018016B2 (en) | 2021-08-18 | 2024-06-25 | Amgen Inc. | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors |
| WO2023023534A2 (fr) | 2021-08-18 | 2023-02-23 | Chemocentryx, Inc. | Composés d'arylsulfonyle en tant qu'inhibiteurs de ccr6 |
| TW202329937A (zh) * | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| WO2023107705A1 (fr) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Amines bicycliques utilisées comme inhibiteurs de cdk12 |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| JP2025528794A (ja) * | 2022-08-08 | 2025-09-02 | インシリコ メディシン アイピー リミテッド | サイクリン依存性キナーゼ（ｃｄｋ）１２および／またはｃｄｋ１３の阻害剤、ならびにその使用 |
| WO2025167975A1 (fr) * | 2024-02-07 | 2025-08-14 | Insilico Medicine Ip Limited | Inhibiteur cristallin de kinase dépendante de la cycline (cdk) 12 et/ou cdk13 et ses utilisations |
| WO2025167978A1 (fr) * | 2024-02-07 | 2025-08-14 | Insilico Medicine Ip Limited | Combinaisons d'inhibiteurs de kinase dépendante des cyclines (cdk) 12 et/ou cdk13 et leurs utilisations |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU657424B2 (en) * | 1992-07-02 | 1995-03-09 | Otsuka Pharmaceutical Co., Ltd. | Oxytocin antagonist |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US20070004763A1 (en) | 2005-06-10 | 2007-01-04 | Nand Baindur | Aminoquinoline and aminoquinazoline kinase modulators |
| JP6097289B2 (ja) | 2011-08-04 | 2017-03-15 | アレイ バイオファーマ、インコーポレイテッド | セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物 |
| US20140309184A1 (en) | 2011-09-21 | 2014-10-16 | University Of South Alabama | Methods and compositions for the treatment of ovarian cancer |
| CA2856291C (fr) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de la kinase c-jun-n-terminale (jnk) |
| EP3057955B1 (fr) | 2013-10-18 | 2018-04-11 | Syros Pharmaceuticals, Inc. | Composes heteroaromatiques utiles dans le traitement de maladies proliferatives |
| AU2014337067B2 (en) * | 2013-10-18 | 2019-01-24 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| TWI601712B (zh) * | 2014-11-05 | 2017-10-11 | 達特神經科學（開曼）有限責任公司 | 作為ｇｌｙｔ１抑制劑之經取代之氮雜環丁基化合物 |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| HK1246645A1 (zh) * | 2015-03-27 | 2018-09-14 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| CA2987552A1 (fr) | 2015-06-04 | 2016-12-08 | Aurigene Discovery Technologies Limited | Derives heterocyclyle substitues en tant qu'inhibiteurs de cdk |
| US10702527B2 (en) * | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP3313530B1 (fr) * | 2015-06-26 | 2022-10-05 | Dana Farber Cancer Institute, Inc. | Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci |
| EP3347018B1 (fr) | 2015-09-09 | 2021-09-01 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dépendantes |
| GB201605126D0 (en) | 2016-03-24 | 2016-05-11 | Univ Nottingham | Inhibitors and their uses |
| WO2018098361A1 (fr) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase 12 dépendante des cyclines (cdk12) et leurs utilisations |
| AU2017379796B2 (en) * | 2016-12-19 | 2021-10-21 | Isocure Biosciences Inc. | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
| US20200197392A1 (en) * | 2017-08-15 | 2020-06-25 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating tuberous sclerosis complex |
| GB201715342D0 (en) | 2017-09-22 | 2017-11-08 | Univ Nottingham | Compounds |
| EP3787629A4 (fr) | 2018-05-02 | 2022-01-05 | Kinnate Biopharma Inc. | Inhibiteurs de kinases dépendantes des cyclines |
| SG11202013175SA (en) | 2018-06-29 | 2021-01-28 | Kinnate Biopharma Inc | Inhibitors of cyclin-dependent kinases |
| JP2022540671A (ja) | 2019-07-17 | 2022-09-16 | キネート バイオファーマ インク． | サイクリン依存性キナーゼの阻害剤 |
| JP2023508996A (ja) | 2019-12-31 | 2023-03-06 | キネート バイオファーマ インク． | Ｃｄｋ１２／１３阻害剤を用いる癌の処置 |
-
2019
- 2019-06-28 SG SG11202013175SA patent/SG11202013175SA/en unknown
- 2019-06-28 EP EP19825341.1A patent/EP3813819A4/fr not_active Withdrawn
- 2019-06-28 JP JP2020571485A patent/JP2021529740A/ja active Pending
- 2019-06-28 KR KR1020217002677A patent/KR20210040368A/ko not_active Abandoned
- 2019-06-28 MX MX2020014245A patent/MX2020014245A/es unknown
- 2019-06-28 BR BR112020026748-1A patent/BR112020026748A2/pt not_active Application Discontinuation
- 2019-06-28 AU AU2019291935A patent/AU2019291935A1/en not_active Abandoned
- 2019-06-28 CA CA3104131A patent/CA3104131A1/fr active Pending
- 2019-06-28 AR ARP190101813A patent/AR115646A1/es not_active Application Discontinuation
- 2019-06-28 CN CN201980057125.9A patent/CN112638373A/zh active Pending
- 2019-06-28 TW TW108122977A patent/TW202016094A/zh unknown
- 2019-06-28 US US16/457,400 patent/US10894788B2/en not_active Expired - Fee Related
- 2019-06-28 WO PCT/US2019/039959 patent/WO2020006497A1/fr not_active Ceased
-
2020
- 2020-11-11 US US17/095,672 patent/US11390618B2/en active Active
- 2020-12-27 IL IL279791A patent/IL279791A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200024266A1 (en) | 2020-01-23 |
| US20210130340A1 (en) | 2021-05-06 |
| KR20210040368A (ko) | 2021-04-13 |
| CN112638373A (zh) | 2021-04-09 |
| EP3813819A4 (fr) | 2022-08-17 |
| WO2020006497A1 (fr) | 2020-01-02 |
| US10894788B2 (en) | 2021-01-19 |
| US11390618B2 (en) | 2022-07-19 |
| IL279791A (en) | 2021-03-01 |
| JP2021529740A (ja) | 2021-11-04 |
| BR112020026748A2 (pt) | 2021-03-30 |
| EP3813819A1 (fr) | 2021-05-05 |
| AU2019291935A1 (en) | 2021-02-04 |
| CA3104131A1 (fr) | 2020-01-02 |
| MX2020014245A (es) | 2021-05-12 |
| TW202016094A (zh) | 2020-05-01 |
| AR115646A1 (es) | 2021-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279791A (en) | Inhibitors of cyclin-dependent kinases | |
| IL292422A (en) | Cyclin-dependent kinase 7 (cdk7) inhibitors | |
| EP3273966A4 (fr) | Inhibiteurs de kinases cycline-dépendantes | |
| SG11202104438VA (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| ZA202101138B (en) | Covalent inhibitors of kras | |
| IL267215A (en) | Imidazopyrrolopyridines as inhibitors of the jak family of kinases | |
| SG11201608242XA (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| IL271930A (en) | Heterocyclic inhibitors of ATR kinase | |
| EP3236959A4 (fr) | Inhibiteurs de la kinase cycline-dépendante 7 (cdk7) | |
| IL312670A (en) | Imidazole-containing ALK2 kinase inhibitors | |
| IL279949A (en) | Heterocyclic MCT4 inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| PT3613737T (pt) | Novo inibidor de cinase cdk9 dependente de ciclina | |
| SI3700902T1 (sl) | Inhibitorji trpc6 | |
| IL275457A (en) | Spiro exo-aza inhibitors of the MENIN-MLL interaction | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| EP3902801A4 (fr) | Inhibiteurs de kinases cycline-dépendantes | |
| IL274015A (en) | Inhibitors of tyrosine-kinases from the mutant Agfer family | |
| SG11202008851UA (en) | Morpholine derivates as inhibitors of vps34 | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL277866B1 (en) | Aminothiazoles were substituted as nuclease inhibitors | |
| EP3877364A4 (fr) | Inhibiteurs de kinases rock | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| HK40073176A (en) | Inhibitors of cyclin-dependent kinases | |
| TWI922889B (zh) | 含有咪唑之alk2激酶抑制劑 |